Negative Outlook on Biohaven's Experimental Drug Study

25 days ago

Alexis

"And let's wrap up Alexis with Biohaven based in Connecticut. Following this morning in premarket trading, they had a mid-stage study of the company's experimental drug for the treatment of major depressive disorder. It missed the primary endpoint. So that's not good. That is not good. Sounds like it's not working. Well, back to the drawing table."

The commentary highlights that Biohaven's mid-stage study for its experimental drug missed its primary endpoint, sparking repeated negative reactions which indicate that the treatment approach is not working. This serves as a negative catalyst and suggests caution for investors considering the stock.

Related Stocks